{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:30:00Z","timestamp":1783524600050,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The medical science research project of Beijing Medical Health Foundation","award":["YWJKJJHKYJJ-LCYX25002"],"award-info":[{"award-number":["YWJKJJHKYJJ-LCYX25002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18030-w","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:48:06Z","timestamp":1759164486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sugemalimab plus chemotherapy versus chemotherapy for advanced gastric cancer in China: a cost-effectiveness analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Xiaojie","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huide","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"18030_CR1","unstructured":"International Agency for Research on Cancer.Stomach fact sheet. Accessed 28 April 2025. (2022). https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/7-stomachfact-sheet.pdf"},{"issue":"3","key":"18030_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"18030_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China. J. Natl. Cancer Cent. 4 (1), 47\u201353 (2022). https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006 (2024).","journal-title":"J. Natl. Cancer Cent."},{"issue":"1","key":"18030_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang, F. H. et al. The Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. (Lond). 44 (1), 127\u2013172. https:\/\/doi.org\/10.1002\/cac2.12516 (2024).","journal-title":"Cancer Commun. (Lond)"},{"issue":"2","key":"18030_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/imt-2022-0080","volume":"15","author":"YX Wu","year":"2023","unstructured":"Wu, Y. X. et al. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. Immunotherapy 15 (2), 101\u2013115. https:\/\/doi.org\/10.2217\/imt-2022-0080 (2023).","journal-title":"Immunotherapy"},{"issue":"11","key":"18030_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24 (11), 1181\u20131195. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6 (2023).","journal-title":"Lancet Oncol."},{"issue":"10294","key":"18030_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398 (10294), 27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2 (2021).","journal-title":"Lancet"},{"issue":"15","key":"18030_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.2024.28463","volume":"333","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. First-Line Sugemalimab plus chemotherapy for advanced gastric cancer: The GEMSTONE-303 randomized clinical trial. JAMA 333 (15), 1305\u20131314. https:\/\/doi.org\/10.1001\/jama.2024.28463 (2025).","journal-title":"JAMA"},{"issue":"42","key":"18030_CR9","doi-asserted-by":"publisher","first-page":"e35614","DOI":"10.1097\/MD.0000000000035614","volume":"102","author":"S Michelly Gon\u00e7alves Brand\u00e3o","year":"2023","unstructured":"Michelly Gon\u00e7alves Brand\u00e3o, S., Brunner-La Rocca, H. P., Pedroso de Lima, A. C. & Alcides Bocchi, E. A review of cost-effectiveness analysis: From theory to clinical practice. Med. (Baltim). 102 (42), e35614. https:\/\/doi.org\/10.1097\/MD.0000000000035614 (2023).","journal-title":"Med. (Baltim)."},{"key":"18030_CR10","unstructured":"National Bureau of statistic. (2024). https:\/\/data.stats.gov.cn\/english\/easyquery.htm?cn=C01 (accessed on April 28, 2025)."},{"key":"18030_CR11","unstructured":"Liu, G. et al. The China Guidelines for Phaumacoeconomic Evaluation (2020 English Edition) (China Market, 2020)."},{"issue":"4","key":"18030_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams, C., Lewsey, J. D., Mackay, D. F. & Briggs, A. H. Estimation of survival probabilities for use in cost-effectiveness analyses: A comparison of a Multi-state modeling survival analysis approach with partitioned survival and Markov Decision-Analytic modeling. Med. Decis. Mak. 37 (4), 427\u2013439. https:\/\/doi.org\/10.1177\/0272989X16670617 (2017).","journal-title":"Med. Decis. Mak."},{"issue":"2","key":"18030_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40273-013-0123-9","volume":"32","author":"V Diaby","year":"2014","unstructured":"Diaby, V., Adunlin, G. & Montero, A. J. Survival modeling for the Estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: A tutorial. Pharmacoeconomics 32 (2), 101\u2013108. https:\/\/doi.org\/10.1007\/s40273-013-0123-9 (2014).","journal-title":"Pharmacoeconomics"},{"key":"18030_CR14","unstructured":"Central People\u2019s Government of the People\u2019s Republic of China. The State Council Office of the People\u2019s Republic of China held a press conference on the Report on the Nutrition and Chronic Disease Status of Chinese Residents (2020). Accessed on April 28, (2025). https:\/\/www.gov.cn\/xinwen\/2020-12\/23\/content_5572785.htm"},{"key":"18030_CR15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hec.673","volume":"11","author":"A Tsuchiya","year":"2002","unstructured":"Tsuchiya, A. et al. Estimating an EQ-5D population value set: The case of Japan. Health Econ. 11, 341\u2013353 (2002).","journal-title":"Health Econ."},{"key":"18030_CR16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"18030_CR17","unstructured":"YaoZH. Drug Pice. (2025). Available at: https:\/\/data.yaozh.com\/ (Accessed on April 28, 2025)."},{"issue":"18","key":"18030_CR18","doi-asserted-by":"publisher","first-page":"18447","DOI":"10.1002\/cam4.6389","volume":"12","author":"Y Lang","year":"2023","unstructured":"Lang, Y., Lin, Y., Li, D., Liu, J. & Liu, X. Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis. Cancer Med. 12 (18), 18447\u201318459. https:\/\/doi.org\/10.1002\/cam4.6389 (2023).","journal-title":"Cancer Med."},{"key":"18030_CR19","doi-asserted-by":"publisher","first-page":"1461571","DOI":"10.3389\/fphar.2024.1461571","volume":"15","author":"W Lang","year":"2024","unstructured":"Lang, W. et al. Cost-effectiveness analysis of Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: Perspectives from the united States and China. Front. Pharmacol. 15, 1461571. https:\/\/doi.org\/10.3389\/fphar.2024.1461571 (2024).","journal-title":"Front. Pharmacol."},{"issue":"8","key":"18030_CR20","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737167.2024.2378986","volume":"24","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z., Song, X., Cai, H. & Zhu, H. Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: A cost-effectiveness analysis. Expert Rev. Pharmacoecon Outcomes Res. 24 (8), 1017\u20131025. https:\/\/doi.org\/10.1080\/14737167.2024.2378986 (2024).","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"issue":"1","key":"18030_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12962-023-00476-2","volume":"21","author":"PF Zhang","year":"2023","unstructured":"Zhang, P. F., Shi, X. Q. & Li, Q. Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A cost-effectiveness analysis. Cost Eff. Resour. Alloc. 21 (1), 65. https:\/\/doi.org\/10.1186\/s12962-023-00476-2 (2023).","journal-title":"Cost Eff. Resour. Alloc"},{"issue":"7","key":"18030_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/17474124.2017.1312342","volume":"11","author":"Y Nie","year":"2017","unstructured":"Nie, Y. et al. A global burden of gastric cancer: The major impact of China. Expert Rev. Gastroenterol. Hepatol. 11 (7), 651\u2013661. https:\/\/doi.org\/10.1080\/17474124.2017.1312342 (2017).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"18030_CR23","unstructured":"American Cancer Society [https:\/\/www.cancer.org\/cancer\/stomach-cancer\/detection-diagnosis-staging\/ survival-rates.html]Date Accessed April 28, 2025."},{"key":"18030_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3332\/ecancer.2018.883","volume":"12","author":"M Casamayor","year":"2018","unstructured":"Casamayor, M., Morlock, R., Maeda, H. & Ajani, J. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience 12, 883. https:\/\/doi.org\/10.3332\/ecancer.2018.883 (2018).","journal-title":"Ecancermedicalscience"},{"issue":"8","key":"18030_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/11310250-000000000-00000","volume":"27","author":"G Baio","year":"2009","unstructured":"Baio, G. & Russo, P. A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes. Pharmacoeconomics 27 (8), 645\u2013655. https:\/\/doi.org\/10.2165\/11310250-000000000-00000 (2009).","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"18030_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.21037\/tlcr.2019.08.09","volume":"8","author":"Y Xu","year":"2019","unstructured":"Xu, Y. et al. The association of PD-L1 expression with the efficacy of anti-PD-1\/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: A meta-analysis of randomized controlled trials. Transl Lung Cancer Res. 8 (4), 413\u2013428. https:\/\/doi.org\/10.21037\/tlcr.2019.08.09 (2019).","journal-title":"Transl Lung Cancer Res."},{"issue":"8","key":"18030_CR27","doi-asserted-by":"publisher","first-page":"9282","DOI":"10.1002\/cam4.5676","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1\/PD-L1 inhibitors: A systematic review and meta-analysis. Cancer Med. 12 (8), 9282\u20139292. https:\/\/doi.org\/10.1002\/cam4.5676 (2023).","journal-title":"Cancer Med."},{"key":"18030_CR28","doi-asserted-by":"crossref","first-page":"1620663","DOI":"10.3389\/fpubh.2025.1620663","volume":"13","author":"L Tang","year":"2025","unstructured":"Tang, L., Zhu, L., Zhan, S., Chen, Y. & Feng, P. F. Cost-effectiveness analysis of Sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer. Front. Public. Health. 13, 1620663 (2025).","journal-title":"Front. Public. Health"},{"issue":"10","key":"18030_CR29","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1007\/s12325-023-02594-y","volume":"40","author":"R Cheng","year":"2023","unstructured":"Cheng, R., Zhou, Z. & Liu, Q. The cost-effectiveness of sugemalimab plus chemotherapy as first-line treatment for metastatic squamous and non-squamous NSCLC in China. Adv. Ther. 40 (10), 4298\u20134309. https:\/\/doi.org\/10.1007\/s12325-023-02594-y (2023).","journal-title":"Adv. Ther."},{"key":"18030_CR30","doi-asserted-by":"publisher","first-page":"1396761","DOI":"10.3389\/fphar.2024.1396761","volume":"15","author":"H Cai","year":"2024","unstructured":"Cai, H., Fang, L. & Zheng, Z. Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis. Front. Pharmacol. 15, 1396761. https:\/\/doi.org\/10.3389\/fphar.2024.1396761 (2024).","journal-title":"Front. Pharmacol."},{"key":"18030_CR31","doi-asserted-by":"publisher","first-page":"175883592311710","DOI":"10.1177\/17588359231171038","volume":"15","author":"X Cao","year":"2023","unstructured":"Cao, X. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: A cost-effectiveness analysis. Ther. Adv. Med. Oncol. 15, 17588359231171038. https:\/\/doi.org\/10.1177\/17588359231171038 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"8","key":"18030_CR32","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/14737167.2024.2378983","volume":"24","author":"W Lang","year":"2024","unstructured":"Lang, W., Deng, L., Lu, M. & Ouyang, M. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric\/gastroesophageal junction cancer in the Chinese healthcare system. Expert Rev. Pharmacoecon Outcomes Res. 24 (8), 1027\u20131042. https:\/\/doi.org\/10.1080\/14737167.2024.2378983 (2024).","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"18030_CR33","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods, B. S., Sideris, E., Palmer, S., Latimer, N. & Soares, M. Partitioned survival and state transition models for healthcare decision making in oncology: Where are we now. Value Health. 23, 1613\u20131621 (2020).","journal-title":"Value Health"},{"key":"18030_CR34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jval.2025.03.014","volume":"28","author":"R Mudumba","year":"2025","unstructured":"Mudumba, R., Nieva, J. J. & Padula, W. V. First-Line alectinib, brigatinib, and lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: A cost-effectiveness analysis. Value Health. 28, 1018\u20131028 (2025).","journal-title":"Value Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18030-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:48:09Z","timestamp":1759164489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18030-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18030"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18030-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study does not involve the use of human or animal. Ethical considerations are not applicable to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"33529"}}